Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin

NCT07390617 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07390617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07390617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Observational
Overall status
Recruiting
Start date
January 20, 2026
Completion date
January 20, 2028
Enrollment
50 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial carcinoma, neuropathy, urothelial carcinoma